Reduced serum brain-derived neurotrophic factor in patients with first onset vitiligo

Yanik M. E., ERFAN G., Albayrak Y., Aydin M., Kulac M., Kuloglu M. M.

NEUROPSYCHIATRIC DISEASE AND TREATMENT, vol.10, pp.2361-2367, 2014 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 10
  • Publication Date: 2014
  • Doi Number: 10.2147/ndt.s74826
  • Journal Name: NEUROPSYCHIATRIC DISEASE AND TREATMENT
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.2361-2367
  • Keywords: neurotrophin, psychosomatic, skin, disease, NERVE GROWTH-FACTOR, LIFE QUALITY INDEX, ATOPIC-DERMATITIS PATIENTS, KERATINOCYTE APOPTOSIS, PSYCHIATRIC MORBIDITY, MAJOR DEPRESSION, HUMAN EPIDERMIS, MOOD DISORDERS, HAIR FOLLICLE, SUBSTANCE-P
  • Acibadem Mehmet Ali Aydinlar University Affiliated: No

Abstract

Purpose: Vitiligo is an acquired pigmentary skin disease that can cause serious cosmetic problems. There have been numerous and well established studies that have demonstrated the comorbidity of various psychiatric disorders in patients with vitiligo. However, to our knowledge, there have been no studies investigating whether a psychiatric biomarker, such as brain-derived neurotrophic factor (BDNF), is associated with vitiligo.